Preventing first heart attacks may be more achievable than previously understood. This finding challenges the traditional approach of waiting for cardiovascular disease to manifest before initiating aggressive cholesterol-lowering therapy, particularly for patients with diabetes or existing atherosclerosis who haven't yet experienced major cardiac events.
The PCSK9 inhibitor evolocumab reduced major adverse cardiovascular events by 25% in patients without prior heart attack or stroke over 4.6 years of treatment. Among 12,257 participants with atherosclerosis or diabetes and LDL cholesterol above 90 mg/dL, those receiving evolocumab experienced 336 major events compared to 443 in the placebo group. The medication demonstrated consistent benefit across both three-point and four-point composite endpoints, suggesting robust protective effects.
This represents a significant expansion of PCSK9 inhibitor applications beyond established cardiovascular disease. Previous trials focused on secondary prevention—patients who already suffered heart attacks or strokes. The current results provide the first definitive evidence for primary prevention benefits in high-risk populations. However, the study population was predominantly White (93%) with median age 66, limiting generalizability to younger or more diverse populations. Cost-effectiveness remains a critical consideration, as PCSK9 inhibitors carry substantial expense compared to statins. The absolute risk reduction, while meaningful, translates to treating approximately 56 patients for five years to prevent one major cardiovascular event. This positions evolocumab as a valuable but selective tool for primary prevention in carefully chosen high-risk patients who cannot achieve target cholesterol levels through conventional therapy.